2010 USRDS Annual Data Report
This Chapter
Download
Download PDF
Download all slides
*corresponding data in Excel included
Search This Page
Search All
Translate

Figure List
Figure 7.1Trends in transplantation: unadjusted rates, wait list, &total transplants, patients age 20 &older
Figure 7.2Wait list counts &multiple listings
Figure 7.3Percent of new listings willing to accept an ECD kidney, by state, 20072008
Figure 7.4Distribution of wait-listed patients, by age, race, PRA, &blood type
Figure 7.5Observed &projected median wait times by year of listing, overall &by age, race, PRA, &blood type (dashed lines show projected times)
Figure 7.6Unadjusted median wait times (years) for adults transplanted in 2008, by state
Figure 7.7Unadjusted projected median wait times (years) for adults listed in 2008, by state
Figure 7.8Wait-listed patients receiving a living donor tx within one year of listing, by age
Figure 7.9Wait-listed pts receiving a deceased donor tx w/i 3 years of listing, by age &blood type
Figure 7.10Outcomes for first-time wait-listed patients three years after listing, 2005, by age, race, &PRA
Figure 7.11Adj. mortality rates (per 100 person yrs of waiting) for wait-listed pts, by state, 2008
Figure 7.12Likelihood of dying while awaiting transplant
Figure 7.13Donation rates, by age, gender, &race
Figure 7.14Deceased donor donations (per 1,000 deaths), by state, 20072008
Figure 7.15Number of transplants from living donors, by donor relation
Figure 7.16Deceased donor transplants from ECD &DCD donors
Figure 7.17Kidney donor risk index (KDRI) &ECD status, 2008
Figure 7.18Adjusted transplant rates, by age, gender, race, &primary diagnosis: overall
Figure 7.19Adjusted transplant rates, by age, gender, race, &primary diagnosis: deceased donors
Figure 7.20Adjusted transplant rates, by age, gender, race, &primary diagnosis: living donors
Figure 7.21Adjusted transplant rates (per 100 dialysis patient years), by state &donor type, 2008
Figure 7.22Transplants with delayed graft function (DGF), by donor type
Figure 7.23Median length of stay for transplant hospitalizations
Figure 7.24Transplants with primary non-function, by donor type
Figure 7.25Acute rejection within the first year post-transplant
Figure 7.26Distribution of transplant recipients, by donor type &eGFR (ml/min/1.73 m2) at discharge
Figure 7.27Distribution of transplant recipients, by donor type &eGFR (ml/min/1.73 m2) 12 months post-transplant
Figure 7.28Immunosuppression use
Figure 7.29Induction antibody use
Figure 7.30Antibiotic use in the first six months post-transplant, 2007 (Part D data)
Figure 7.31Follow-up care &screening in the first 12 months post-transplant, by age
Figure 7.32Cardiovascular medication use in the first 6 months post-tx, 2007 (Part D data)
Figure 7.33Medications for lipid &DM control in the first 6 months post-tx, 2007 (Part D data)
Figure 7.34Outcomes: deceased donor transplants
Figure 7.35Outcomes: living donor transplants
Figure 7.36Hospitalization rates in the first &second years post-transplant
Figure 7.37Primary diagnoses of cardiac &infectious hospitalizations in the first &second years post-transplant
Figure 7.38Cumulative incidence of post-transplant lymphoproliferative disorder (PTLD)
Figure 7.39Cumulative incidence of post-transplant malignancies other than PTLD
Figure 7.40Cumulative incidence of post-transplant diabetes
Figure 7.41Cumulative incidence of post-transplant BK infection
Figure 7.42Estimated glomerular filtration rate, by year post-transplant &donor type
Figure 7.43Adjusted hazard ratio of five-year all-cause graft failure, by one-year eGFR
Figure 7.44Adjusted rate of outcomes after transplant
Figure 7.45Causes 0f death with function, 20042008
Figure 7.46Pre-transplant transfusion status of transplanted patients, by gender
Figure 7.47Median waiting time, by transfusion status
Figure 7.48Three-year cumulative incidence of transfusion in wait-listed patients, by PRA
Figure 7.49Distribution of wait listed patients
Figure 7.50Effect of pre-transplant transfusion on the risk of elevated PRA in transplant patients, by gender, 20042008
Figure 7.51Association between transfusions &five-year mortality &transplant rates

Chapter Seven
Transplantation  Top

Sections this chapter: 

In 2008, the most recent year of available data, 17,413 kidney transplants were performed in the U.S. slightly fewer than in the previous year, and continuing the decline from a high of 18,059 in 2006. This decline was seen in both deceased and living donor transplants, at 0.6 and 1.2 percent, respectively. It also occurred among both pediatric and adult recipients. The fall in the number of transplants is contemporaneous with a continued decline in the unadjusted rate of new cases of end-stage renal disease, which fell 1.3 percent from a high of 498.1 cases per million population in 2006. The number of patients on the kidney transplant wait list, however, continues to increase sharply, growing 6 percent in 2008, and reaching more than 77,000 at the end of the year. But at the end of 2008, only 66 percent of the total kidney wait list was designated as active, yielding an active list of 51,585 patients.

The use of expanded criteria donors had plateaued at 20 percent in 20052007, but increased slightly in 2008 to 22 percent of all deceased donor transplants performed. And the use of kidneys from donations after cardiac death continues to rise; these donations now constitute 12 percent of all donations from deceased donors.

While the total number of transplants from live donors age 20 and older fell 10 percent between 2004 and 2008, reported transplants from kidney paired donation programs increased eight-fold in the same period, reaching 339 reported transplants in 2008. Transplants from paired donations currently make up only 2 percent of transplants performed in the United States. The number of donations from living relations continues to decline, and is now 20 percent lower than that observed in 2004. Donations from spouses or distant relatives have remained fairly constant.

Wait times continue to increase nationwide. For patients entering the wait list in 2005, the most recent year in which 50 percent of wait listed patients had been transplanted, the median time to receive a deceased donor transplant was 3.0 years. Patients with blood type B wait the longest, with a median of 4.0 years for patients listed in 2005, while patients with blood type AB have the shortest waits, with a median of 1.3 years. Unsensitized patients those with a zero percent panel-reactive antibody (PRA) at the time of listing have the shortest wait times, a median of 2.5 years in 2005, while those with a PRA of 119 and 2079 percent have median wait times of 2.9 and 4.3 years, respectively. Highly sensitized patients, those with a PRA of 80 percent and above, wait the longest, with median wait times still to be observed for patients listed in 2005. Of those added to the wait list in 2003, 17, 19, and 16 percent of white, African American, and Asian patients, respectively, died within five years awaiting a transplant, and 14, 21, and 25 percent were still waiting for a transplant at the end of that period.

Adjusted one-year survival with a functioning transplant has continued to reach all-time highs, at 91 percent for recipients of first-time, deceased donor transplants and 96 percent for recipients of first-time, living donor transplants in 2007. Attention continues to focus on reducing the incidence of acute rejection and other post-transplant complications, and on improving long-term transplant outcomes. The incidence of reported acute rejection episodes during the first year post-transplant has declined more than 50 percent over the past decade, and was reported in 12 percent of deceased donor recipients and 11 percent of living donor recipients in 2007. New-onset diabetes following transplant remains common, with over 40 percent of adult recipients having evidence of diabetes by the end of the third year after transplant. Post-transplant lymphoproliferative disorders are reported in 0.5 percent of adult recipients and 2.0 percent of pediatric recipients through three years post-transplant. Congestive heart failure remains the leading cause of cardiovascular hospitalizations during the first two years post-transplant, while urinary tract infections are the leading cause of infectious hospitalizations during the first two years post-transplant. And among recipients who die with a functioning transplant, cardiovascular disease continues to be the leading cause of death, accounting for 30 percent of deaths, followed by infectious causes at 21 percent and malignancies at 10 percent.

The use of pre-transplant blood transfusions remains common among transplant recipients, with 15 percent of 2008 recipients receiving at least one such transfusion. Among patients on the wait-list, the percentage who receive at least one transfusion within the first three years on the list has remained relatively constant over the past decade, at approximately 28 percent. The use of transfusions among unsensitized patients is similar to that of patients with low and mid levels of sensitization, suggesting that transfusion avoidance may need more attention. There is a positive association between the use of pre-transplant blood transfusion and the odds of elevated PRA at the time of transplant, and receiving a blood transfusion while on the wait list is associated with increased rates of death while on the list and with a reduced likelihood of receiving a transplant.

Figure 7.1 Trends in transplantation: unadjusted rates, wait list, &total transplants, patients age 20 &older (see page 477 for analytical methods. Unadjusted incident &transplant rates: limited to ESRD patients age 20 &older, thus yielding a computed incident rate higher than the overall rate presented elsewhere in the Annual Data Report. Wait list counts: patients age 20 &older listed for a kidney or kidney-pancreas transplant on December 31 of each year. Wait time: patients age 20 &older entering wait list in the given year. Transplant counts: patients age 20 &older as known to the USRDS)

Kidney transplant wait list  Top

Figure 7.2 Wait list counts &multiple listings

On December 31, 2008, there were 51,585 active patients on the wait list for a kidney or kidney-pancreas transplant, and 25,189 inactive patients.

Figure 7.3 Percent of new listings willing to accept an ECD kidney, by state, 20072008

The percentage of new listings willing to accept an ECD kidney averaged 75.8 for patients residing in states represented by the upper quintile.

Figures 7.23; see page 477 for analytical methods. Patients age 18 &older listed for a kidney or kidney-pancreas transplant on December 31 of each year (7.2); newly listed adults (7.3).

Figure 7.4 Distribution of wait-listed patients, by age, race, PRA, &blood type

In 1991, just three in ten patients wait-listed for a kidney or kidney-pancreas transplant were age 50 or older. By 2008 this number had doubled, and one in six patients is now 65 or older. Distribution by panel-reactive antibody (PRA) level has also changed; nearly one in two patients now has a PRA of zero, up from 24 percent in 1991. There has been less variation in patient distribution by race; 46 percent of wait-listed patients in 2008 were non-white, compared to 39 percent in 1991.

Figure 7.5 Observed &projected median wait times by year of listing, overall &by age, race, PRA, &blood type (dashed lines show projected times)

The median wait time for patients listed in 2005, the most recent observation year, was 3.0 years; for those listing in 2010, this is projected to reach 3.6 years. By race, projected times for patients listing in 2010 range from 2.3 years for whites to 3.7 years for African Americans. Wait times continue to be longest for sensitized patients, particularly for those who are highly sensitized. And wait times vary widely by blood type, from a projected 1.9 years for AB patients listing in 2010 to 4.1 years for those with blood type O.

Figures 7.45; see page 477 for analytical methods. Patients age 18 &older listed for a kidney or kidney-pancreas transplant on December 31 of each year (7.4); patients age 18 &older listed for a first-time, kidney-only transplant in the given year; *estimates for PRA of 80 &above are unstable &are therefore omitted (7.5).

Figure 7.6 Unadjusted median wait times (years) for adults transplanted in 2008, by state

Median wait times for adults transplanted in 2008 exceeded three years in Alabama, Hawaii, New Jersey, California, and Illinois, while the nationwide median was 2.1 years.

Figure 7.7 Unadjusted projected median wait times (years) for adults listed in 2008, by state

Projected median wait times for listed adults in California and Alabama were 7.2 and 9.3 years, respectively.

Figures 7.67; see page 478 for analytical methods. Patients age 18 &older receiving (7.6) or listed for (7.7) a first-time, deceased-donor, kidney-only transplant in 2008. State is state of transplant center.

Figure 7.8 Wait-listed patients receiving a living donor tx within one year of listing, by age

Of patients wait-listed in 2007, 12.3 percent had a live-donor transplant within one year, from 24.7 percent of pediatric patients to 8.4 percent of those 65 and older. .

Figure 7.9 Wait-listed pts receiving a deceased donor tx w/i 3 years of listing, by age &blood type

Within three years of listing in 2005, 79 percent of wait-listed children had a deceased donor transplant, and 34 percent of adults 27 percent of those with blood type O or B, and 63 percent of those with AB.

Figures 7.89; see page 478 for analytical methods. Patients listed for a first-time kidney or kidney-pancreas transplant

Figure 7.10 Outcomes for first-time wait-listed patients three years after listing, 2005, by age, race, &PRA (see page 478 for analytical methods. Pts age 18 &older listed for a first-time, kidney-only transplant in 2005; transplanted patients may have subsequent outcomes in the three-year follow-up period)

Of patients listed in 2005, 28, 26, and 25 percent of whites, African Americans, and Asians, respectively, received a deceased donor transplant within three years of listing; 50, 35, and 41 percent received either a deceased or live donor transplant in this period. Variation also exists by age and PRA.

Figure 7.11 Adj. mortality rates (per 100 person yrs of waiting) for wait-listed pts, by state, 2008

Adjusted mortality rates among wait-listed patients are highest in the Gulf Coast states, Montana, West Virginia, and Rhode Island, averaging 9.4 in the upper quintile.

Figure 7.12 Likelihood of dying while awaiting transplant

For first-time transplant candidates, the probabilities of dying within one or five years of listing reached 0.03 and 0.27, respectively, in 2008.

Figures 7.1112; see page 478 for analytical methods. Pts age 18 &older, listed for a kidney or kidney-pancreas tx as of Jan. 1, 2008 (7.11), or listed for a first-time kidney or kidney-pancreas tx (7.12). See appendix for adjustments.

Kidney donation & transplantation  Top

Figure 7.13 Donation rates, by age, gender, &race (see page 478 for analytical methods. Donors younger than 70 whose organs are eventually transplanted)

Rates of kidney donation from deceased donors remain highest among those age 4559 and among males, reaching 29.5 and 26.6 per million population, respectively, in 2008. Since 2005, rates by race have been highest in the African American population, reaching 26.1 in 2008, compared to just 9.810.1 among Native Americans and Asians.

While deceased donor donation rates have remained quite steady since 2006, rates of donations from living donors have been declining among many groups 19 percent since 2004 for male donors, and 22 percent for African Americans. Rates by gender are 55 percent greater among women compared to men, at 26.2 and 16.9 per million population, respectively.

Figure 7.14 Deceased donor donations (per 1,000 deaths), by state, 20072008

In 20072008, the rate of donations from deceased donors was 2.5 per 1,000 deaths overall; rates by state were greatest in Utah, Wisconsin, Delaware, and Alaska.

Figure 7.15 Number of transplants from living donors, by donor relation

The number of transplants from a kidney paired donation rose from 212 in 2007 to 339 in 2008. Transplants from related donors, in contrast, have fallen 22 percent from their peak in 2001, to 3,045.

Figures 7.1415; see page 478 for analytical methods. Deaths from July 1, 2007 to July 1, 2008 (7.14); all patients receiving a living donor kidney transplant (7.15).

Figure 7.16 Deceased donor transplants from ECD &DCD donors

Twenty-two percent of deceased donor transplants in 2008 were from an expanded criteria donor (ECD); one in eight was a donation after cardiac death (DCD).

Figure 7.17 Kidney donor risk index (KDRI) &ECD status, 2008

The Kidney Donor Risk Index (KDRI) is increasingly being used to rate deceased donor quality. As the KDRI score increases, the likelihood of being designated ECD also increases.

Figures 7.1617; see page 478 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only, deceased donor transplant, 19912008 (7.16) &2008 (7.17).

Figure 7.18 Adjusted transplant rates, by age, gender, race, &primary diagnosis: overall

Since 2000, the overall adjusted transplant rate has fallen 2930 percent for patients age 1849; among those 65 and older, in contrast, it has increased nearly 49 percent. By race, the rate continues to fall for whites, remains relatively steady for African Americans, and for Asians has grown 35 percent since 2000.

Figure 7.19 Adjusted transplant rates, by age, gender, race, &primary diagnosis: deceased donors

Deceased donor transplant rates show similar patterns. By age, the rate for patients age 1834 has fallen 33 percent since 2000, reaching 5.3 per 100 dialysis patient years, while that for patients age 65 and older is now 1.1, almost 54 percent greater than in 2000.

Figure 7.20 Adjusted transplant rates, by age, gender, race, &primary diagnosis: living donors

(see page 478 for analytical methods. Patients age 18 &older. Adj: age/gender/race/primary diagnosis; ref: prevalent dialysis patients, 2008. State is state of patient residence)

Rates of transplants from living donors peaked at the beginning of the decade, and have since fallen for many patient groups. As with rates overall and for deceased donors, rates by race are now greatest in the Asian population, reaching 2.7 in 2008 58 percent higher than in 2000.

Figures 7.1820; see page 478 for analytical methods. Patients age 18 &older. Adj: age/gender/race/primary diagnosis; ref: prevalent dialysis patients, 2008.

Figure 7.21 Adjusted transplant rates (per 100 dialysis patient years), by state &donor type, 2008

By state, the highest overall transplant rates are reported in the Upper Midwest and the northeast states, with rates of 6.8 per 100 patient years or above in Wisconsin, Minnesota, North Dakota, and Vermont. In Minnesota and Vermont, rates of transplants from living donors in 2008 reached 3.8 and 4.2, respectively.

Transplant discharge &follow-up  Top

Figure 7.22 Transplants with delayed graft function (DGF), by donor type

In 2008, DGF was reported in 3.6 percent of transplants from living donors, compared to 21.3, 29.6, and 40.2 percent of those from SCDs, ECDs, and donations after cardiac death.

Figure 7.23 Median length of stay for transplant hospitalizations

In 2008, the median length of stay for a transplant hospitalization ranged from five days for adult living donor transplant recipients to nine days for those with delayed graft function.

Figures 7.2223; see page 478 for analytical methods. Patients age 18 &older with functioning graft at discharge (7.2223).

Figure 7.24 Transplants with primary non-function, by donor type

Primary non-function graft failure within seven days of transplant is now reported in 1.8 and 1.0 percent of deceased and living donor adult transplant recipients, respectively.

Figure 7.25 Acute rejection within the first year post-transplant

While the incidence of acute rejection during the first year post-transplant is 11.7 and 11.0 percent. Seventy to 71 percent of reported acute rejections are biopsy-proven.

Figures 7.2425; see page 478 for analytical methods. Pts age 18 &older (7.24); first-time, kidney-only tx recipients, 18+, with functioning graft at discharge (7.25).

Figure 7.26 Distribution of transplant recipients, by donor type &eGFR (ml/min/1.73 m2) at discharge

The distribution of patients by estimated glomerular filtration rate (eGFR) at discharge varies considerably by donor type. In 2008, for example, nearly 48 percent of deceased donor transplant recipients had an eGFR at discharge of less than 30 ml/min/1.73 m2, compared to just 12.7 percent of living donor recipients; eGFRs of 60 or above were reported in 20.2 compared to 45.3 percent, respectively.

Figure 7.27 Distribution of transplant recipients, by donor type &eGFR (ml/min/1.73 m2) 12 months post-transplant

At one year after transplant, however, the distribution is far more similar across donor types, with an eGFR less than 30 ml/min/1.73 m2 found in just 7.3 and 3.3 percent of deceased and living donor recipients transplanted in 2007. Forty-seven and 51 percent of patients had an eGFR of 60 or above.

Figures 7.2627; see page 478 for analytical methods. Patients age 18 &older, discharged with graft function within 15 days of transplant; eGFR computed using CKD-EPI equation (7.26); patients age 18 &older, alive with graft function 12 months post-transplant; eGFR computed using CKD-EPI equation (7.27).

Figure 7.28 Immunosuppression use (see page 479 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only tx. CsA: cyclosporine A; CsM: cyclosporine microemulsion)

Eighty-seven percent of patients transplanted in 2008 used tacrolimus as their initial calcineurin inhibitor. Mycophenolate has almost completely replaced azathioprine in new transplant recipients. And use of mTOR inhibitors, both initially and at one year post-transplant, has continued to fall, as has the use of steroids.

Figure 7.29 Induction antibody use

In 2008, nearly 29 percent of transplant patients received IL-2 RA, and 52.3 percent were on a T-cell depleting antibody; just 18.6 percent received no treatment.

Figure 7.30 Antibiotic use in the first six months post-transplant, 2007 (Part D data)

KDIGO guidelines recommend prophylactic antibiotics in the first three months post-transplant for the prevention of UTI and PCP, and prophylactic antiviral use for the prevention of CMV. ? Figures 7.2930; see page 479 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only transplant (7.30: 2007).

Figure 7.31 Follow-up care &screening in the first 12 months post-transplant, by age (see page 479 for analytical methods. Pts age 18 &older receiving a first-time, kidney-only tx)

In 2008, influenza vaccination rates in the 12 months post-transplant were 2123 percent in patients 1849, and 41 percent in those 65 and older (patients may be vaccinated through non-Medicare programs). Lipid screening rates range from 87 percent in the youngest patients to 94 percent in the oldest. Since 2003, nearly all transplant patients have received a CBC test in the year after transplant.

Figure 7.32 Cardiovascular medication use in the first 6 months post-tx, 2007 (Part D data)

In the first six months post-transplant, diuretic use in patients with Part D coverage is more common for deceased donor recipients than for living donor recipients, at 50 compared to 29 percent..

Figure 7.33 Medications for lipid &DM control in the first 6 months post-tx, 2007 (Part D data)

Statins are used by 3739 percent of patients during this period, and insulin by 3136 percent; 57 and 46 percent of deceased and living donor recipients, respectively, are on an antidiabetic medication.

Figures 7.3233; see page 479 for analytical methods. Pts age 18 &older receiving a first-time, kidney-only tx.

Transplant outcomes  Top

Figure 7.34 Outcomes: deceased donor transplants

Figure 7.35 Outcomes: living donor transplants

Long-term transplant outcomes continue to be a focus of attention. Five-year survival with a functioning graft was 69 and 82 percent for recipients of kidneys from deceased and living donors, respectively, in 2003, up from 58 and 75 percent in 1993. Ten-year survival with a functioning graft was 40 and 58 percent in 1998, up from 34 and 52 percent in 1993. Conditional on surviving the first year with a functioning transplant, at 12.6 years 50 percent of deceased donor transplant recipients are projected to have a functioning graft. For recipients of living donor transplants, this projected half-life is 24.8 years.

Figures 7.3435; see page 479 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only transplant. Adj (survival): age/gender/race/primary diagnosis. Half-life estimate conditional on first-year graft survival.

Figure 7.36 Hospitalization rates in the first &second years post-transplant (see page 479 for analytical methods. First-time, kidney-only tx recipients, age 18 &older, transplanted in 2006; ref: transplant patients, 2005)

In the second year post-transplant, hospitalization rates for adult recipients are 53 percent lower than in the first year, at 68 admissions per 100 patient years. Admissions due to transplant complications fall 70 percent, to 12.3, while cardiovascular and infectious admission rates fall 41 and 49 percent, to 8.9 and 16.7.

Figure 7.37 Primary diagnoses of cardiac &infectious hospitalizations in the first &second years post-transplant (see page 479 for analytical methods. First-time, kidney-only transplant recipients, age 18 &older, with Medicare primary coverage, transplanted in 20042008)

In the first year after transplant, 20.1 percent of cardiovascular hospitalizations are due to congestive heart failure; this rises to 23.1 percent in year two. Hospitalizations for coronary atherosclerosis and CVA/TIA also increase, from 7.4 and 5.5 percent, respectively, in year one to 13.8 and 9.8 percent in year two. Urinary tract infection is the most common diagnosis among transplant patients admitted for infection, at 17.3 percent in the first year and 16.3 in the second.

Figure 7.38 Cumulative incidence of post-transplant lymphoproliferative disorder (PTLD)

At 36 months after transplant, the cumulative incidence of post-transplant lymphoproliferative disorder (PTLD) is four times greater among patients younger than 18 than among their adult counterparts, at 1.99 percent compared to 0.5.

Figure 7.39 Cumulative incidence of post-transplant malignancies other than PTLD

The reported incidence of malignancies other than PTLD is considerably different between the Medicare and OPTN data, reaching 9.9 compared to 2.4 percent, respectively, at 36 months.

Figure 7.40 Cumulative incidence of post-transplant diabetes

Adults, in contrast, have a higher incidence of post-transplant diabetes; more than 40 percent of adult recipients develop diabetes during this period, compared to 12.6 percent of pediatric patients.

Figure 7.41 Cumulative incidence of post-transplant BK infection

Nearly one in five pediatric transplant recipients has a BK infection by 36 months post transplant, compared to 11.1 percent of adult recipients.

Figures 7.3841; see page 479 for analytical methods. Patients receiving a first-time, kidney-only transplant, 20012005 combined.

Figure 7.42 Estimated glomerular filtration rate, by year post-transplant &donor type

Figure 7.43 Adjusted hazard ratio of five-year all-cause graft failure, by one-year eGFR

Compared to those with an eGFR of 6089 ml/min/1.73 m2 at one year post-transplant, patients with an eGFR of 1529 are four times more likely to lose their graft or die with function within the subsequent four-year period.

Figures 7.4243; see page 479 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only transplant (7.42: 20022003; 7.43: 19992003) &alive with graft failure one year post-transplant; see appendix for adjustments. eGFR calculated with CKD-EPI equation.

Figure 7.44 Adjusted rate of outcomes after transplant

Graft failure rates fell to 6.5 per 100 patient years in 2008, while rates of a failure necessitating dialysis or retransplantation and of death with function fell to 3.3 and 3.2.

Figure 7.45 Causes 0f death with function, 20042008

Cardiovascular disease and infection are the main cause of death for 30 and 21 percent of adult patients who die with a functioning graft.

Figures 7.4445; see page 480 for analytical methods. Pts age 18+ at tx; adj: age/gender/race (7.44): ref: 2008 prev. dial. pts. First-time, kidney-only tx recipients, age 18+, 20042008, who died with functioning graft (7.45).

Transfusions &panel-reactive antibodies  Top

Figure 7.46 Pre-transplant transfusion status of transplanted patients, by gender (see page 480 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only transplant)

Reported use of pre-transplant blood transfusions among transplant recipients has continued to decline, falling overall from 49 percent in 1991 to 15 percent in 2008. Transfusions are slightly more common among women than men, at 17.1 compared to 13.4 percent.

Figure 7.47 Median waiting time, by transfusion status (see page 480 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only, deceased donor transplant)

Since 1991, time from first listing to transplant has been increasing for all patients. Those who report a history of transfusion prior to transplant consistently wait longer for a transplant.

Figure 7.48 Three-year cumulative incidence of transfusion in wait-listed patients, by PRA (see page 480 for analytical methods. Patients age 18 &older with Medicare primary coverage &listed for a kidney transplant in the given year)

Use of transfusions among wait-listed patients has remained fairly stable since 1995. Approximately 30 percent of transplant candidates in 2007 had evidence of at least one blood transfusion within three years of being added to the list. Use is greater among patients highly sensitized at the time of transplant (PRA of 80 percent or higher).

Figure 7.49 Distribution of wait listed patients, by PRA &time after listing, 19982003 (see page 480 for analytical methods. Patients age 18 &older listed for a kidney or kidney/pancreas transplant, 19982003)

The distribution of PRA values among patients on the wait list tends toward higher levels of sensitization with longer periods from the date of listing, reflecting the difficulty of finding suitable donors for highly sensitized candidates.

Figure 7.50 Effect of pre-transplant transfusion on the risk of elevated PRA in transplant patients, by gender, 20042008 (see page 480 for analytical methods. Patients age 18 &older receiving a first-time, kidney-only transplant, 20042008)

The odds of reporting PRA elevations at the time of transplant are increased in the presence of a pre-transplant transfusion. A reported pre-transplant transfusion is associated more strongly for men than for women with being highly sensitized at the time of transplant.

Figure 7.51 Association between transfusions &five-year mortality &transplant rates (see page 480 for analytical methods. Patients age 18 &older, with Medicare primary coverage listed for a kidney or kidney/pancreas transplant, 20012005)

Receiving a transfusion while on the transplant wait list is associated with nearly a five-fold higher risk of dying while on the wait list within the first five years, and an 11 percent reduction in the likelihood of receiving a transplant within the first five years.